Cargando…

Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings

Dopamine D2 receptor agonists represent a first line treatment option in young patients with signs and symptoms of idiopathic Parkinson's disease. An association between the use of D2 receptor agonists in Parkinson's disease patients and heart failure has been reported. The identification...

Descripción completa

Detalles Bibliográficos
Autores principales: Abou Farha, Khalid, Baljé-Volkers, Corine, Tamminga, Wim, den Daas, Izaak, van Os, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920609/
https://www.ncbi.nlm.nih.gov/pubmed/24587918
http://dx.doi.org/10.1155/2014/956353
_version_ 1782303197971349504
author Abou Farha, Khalid
Baljé-Volkers, Corine
Tamminga, Wim
den Daas, Izaak
van Os, Sandra
author_facet Abou Farha, Khalid
Baljé-Volkers, Corine
Tamminga, Wim
den Daas, Izaak
van Os, Sandra
author_sort Abou Farha, Khalid
collection PubMed
description Dopamine D2 receptor agonists represent a first line treatment option in young patients with signs and symptoms of idiopathic Parkinson's disease. An association between the use of D2 receptor agonists in Parkinson's disease patients and heart failure has been reported. The identification of the underlying mechanism is needed to minimize the resultant cardiovascular morbidity. In a phase I clinical trial, a D2 receptor agonist (pramipexole) was administered to 52 healthy male subjects following a dose escalation scheme. Serial measurements of resting blood pressure, heart rate, and derived parameters including pulse pressure, pulsatile stress, and rate pressure product were analysed. Statistically significant and clinically relevant increases in most of the assessed parameters were found. Ten subjects were removed prematurely from the trial because of clinically significant increases in blood pressure and/or heart rate requiring immediate intervention with IV rescue medications including a selective β-1 blocker. The observed drug-related changes in vital signs were of clinical relevance and might explain some of the cardiovascular morbidity reported in patients receiving D2 receptor agonist in clinical settings. We suggest that the additional use of a β-1 blocking agent might mitigate the risk of cardiovascular morbidity among patients receiving long-term D2 receptor agonists.
format Online
Article
Text
id pubmed-3920609
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39206092014-03-02 Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings Abou Farha, Khalid Baljé-Volkers, Corine Tamminga, Wim den Daas, Izaak van Os, Sandra ISRN Neurol Clinical Study Dopamine D2 receptor agonists represent a first line treatment option in young patients with signs and symptoms of idiopathic Parkinson's disease. An association between the use of D2 receptor agonists in Parkinson's disease patients and heart failure has been reported. The identification of the underlying mechanism is needed to minimize the resultant cardiovascular morbidity. In a phase I clinical trial, a D2 receptor agonist (pramipexole) was administered to 52 healthy male subjects following a dose escalation scheme. Serial measurements of resting blood pressure, heart rate, and derived parameters including pulse pressure, pulsatile stress, and rate pressure product were analysed. Statistically significant and clinically relevant increases in most of the assessed parameters were found. Ten subjects were removed prematurely from the trial because of clinically significant increases in blood pressure and/or heart rate requiring immediate intervention with IV rescue medications including a selective β-1 blocker. The observed drug-related changes in vital signs were of clinical relevance and might explain some of the cardiovascular morbidity reported in patients receiving D2 receptor agonist in clinical settings. We suggest that the additional use of a β-1 blocking agent might mitigate the risk of cardiovascular morbidity among patients receiving long-term D2 receptor agonists. Hindawi Publishing Corporation 2014-01-22 /pmc/articles/PMC3920609/ /pubmed/24587918 http://dx.doi.org/10.1155/2014/956353 Text en Copyright © 2014 Khalid Abou Farha et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Abou Farha, Khalid
Baljé-Volkers, Corine
Tamminga, Wim
den Daas, Izaak
van Os, Sandra
Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings
title Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings
title_full Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings
title_fullStr Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings
title_full_unstemmed Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings
title_short Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings
title_sort dopamine d2r agonist-induced cardiovascular effects in healthy male subjects: potential implications in clinical settings
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920609/
https://www.ncbi.nlm.nih.gov/pubmed/24587918
http://dx.doi.org/10.1155/2014/956353
work_keys_str_mv AT aboufarhakhalid dopamined2ragonistinducedcardiovasculareffectsinhealthymalesubjectspotentialimplicationsinclinicalsettings
AT baljevolkerscorine dopamined2ragonistinducedcardiovasculareffectsinhealthymalesubjectspotentialimplicationsinclinicalsettings
AT tammingawim dopamined2ragonistinducedcardiovasculareffectsinhealthymalesubjectspotentialimplicationsinclinicalsettings
AT dendaasizaak dopamined2ragonistinducedcardiovasculareffectsinhealthymalesubjectspotentialimplicationsinclinicalsettings
AT vanossandra dopamined2ragonistinducedcardiovasculareffectsinhealthymalesubjectspotentialimplicationsinclinicalsettings